Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing

Florian Selt(German Cancer Research Center), Till Milde(German Cancer Research Center)

Oncotarget

December 17, 2016

10.18632/oncotarget.14004

Cited by 53

Related Papers

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

|Acta Neuropathologica|2016|650

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy

|Nature|2014|621

The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma

|Clinical Cancer Research|2018|84

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma

|Nature Communications|2019|60

Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia

|Clinical Epigenetics|2019|44